NEW YORK (GenomeWeb) – MDxHealth today reported a 36 percent year-over-year increase in its first quarter revenues as sales of its prostate cancer test grew nearly five-fold.

The company said that total revenues were up to $1.9 million for the three months ended March 31, compared to $1.4 million a year ago. Revenues generated from the ConfirmMDx prostate cancer test increased to $1.4 million from $300,000 in Q1 2013, MDxHealth said, as test volume rose to about 2,300 cases in the recently completed quarter from about 900 cases a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.